Parikh, DeRubertis, Bonaca, Krishnan, Pin, Lee, Metzger, Kolluri, Shishehbor, Holden, Iida, Armstrong, Kum, O'Connor, Bajakian, Garcia, Ying, Wang, Ruster, . . . Varcoe (2026). Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.. Journal of the American College of Cardiology.
Parikh, DeRubertis, Bonaca, Krishnan, Pin, Lee, et al. Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.. Journal of the American College of Cardiology. 2026; PMID: 42126372
Parikh, DeRubertis, Bonaca, et al. Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.[J]. Journal of the American College of Cardiology. 2026.
@article{parikh2026,
author = {Parikh and DeRubertis and Bonaca and Krishnan and Pin and Lee and Metzger and Kolluri and Shishehbor and Holden and Iida and Armstrong and Kum and O'Connor and Bajakian and Garcia and Ying and Wang and Ruster and Martinsen and Igyarto and Varcoe},
title = {Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.},
journal = {Journal of the American College of Cardiology},
year = {2026},
note = {PMID: 42126372},
}
TY - JOUR AU - Parikh AU - DeRubertis AU - Bonaca AU - Krishnan AU - Pin AU - Lee AU - Metzger AU - Kolluri AU - Shishehbor AU - Holden AU - Iida AU - Armstrong AU - Kum AU - O'Connor AU - Bajakian AU - Garcia AU - Ying AU - Wang AU - Ruster AU - Martinsen AU - Igyarto AU - Varcoe TI - Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial. T2 - Journal of the American College of Cardiology PY - 2026 AN - PMID:42126372 ER -
Chronic limb-threatening ischemia (CLTI) caused by infrapopliteal disease is a major therapeutic challenge, with percutaneous transluminal angioplasty (PTA) associated with high rates of restenosis and reintervention. The LIFE-BTK trial previously demonstrated superior efficacy of the Esprit (Abbott Vascular) BTK drug-eluting resorbable scaffold (DRS) over PTA at 1 year, with sustained benefits at 2 years, with comparable safety at both time points. This report presents the 3-year outcomes.